# A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

> **NCT06699212** · PHASE3 · RECRUITING · sponsor: **Rakuten Medical, Inc.** · enrollment: 412 (estimated)

## Conditions studied

- Recurrent Head and Neck Squamous Cell Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** ASP-1929 Photoimmunotherapy
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** 5-fluorouracil
- **DRUG:** Paclitaxel
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT06699212
- **Lead sponsor:** Rakuten Medical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-24
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 412 (ESTIMATED)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06699212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06699212, "A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06699212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*